Introduction And Mechanism Of Action

Proton Beam Therapy (PBT) represents the preferred radiation modality for children and adolescents requiring curative-intent radiotherapy.
PBT utilizes the Bragg peak phenomenon to deliver precise radiation dose deposition at a specific target depth.
The beam stops precisely at the tumor target, entirely eliminating the exit dose and preventing unnecessary radiation to developing organs located behind the tumor bed.
It successfully reduces the low-dose radiation bath to uninvolved tissues by 50 to 70 percent, significantly lowering the overall integral dose.

Primary Clinical Indications

Central nervous system (CNS) tumors, specifically medulloblastoma, ependymoma, and craniopharyngioma.
Base-of-skull tumors and parameningeal rhabdomyosarcoma.
Pediatric sarcomas, including Ewing sarcoma.
Neuroblastoma and retinoblastoma.
Complex clinical scenarios requiring re-irradiation.
Patients with underlying genetic cancer predisposition syndromes (e.g., NF1, Retinoblastoma mutation, ATM).

Parameter	Conventional Photon Radiotherapy	Proton Beam Therapy (PBT)
Neurocognitive Outcome	Intelligence Quotient (IQ) decline of 10 to 15 points in medulloblastoma survivors.	Superior IQ preservation with a decline of less than 5 points.
Endocrine And Cardiac Function	High risk of growth hormone deficiency, hypothyroidism, and late cardiac toxicity.	Demonstrates a 20 to 30 percent reduction in late endocrine and cardiac adverse events.
Secondary Malignancies	Lifetime risk of secondary cancers is 5 to 20 percent higher.	Achieves a 50 percent relative reduction in secondary malignancy risk.
Integral Dose	High entry and exit doses to surrounding normal tissue.	30 to 50 percent lower integral dose to normal developing tissues.

American Society for Radiation Oncology (ASTRO) 2025 Model Policy strongly recommends PBT for all pediatric patients aged 21 years or younger undergoing curative-intent radiation.
Children's Oncology Group (COG) and International Society of Paediatric Oncology (SIOP) 2025 protocols incorporate PBT as the standard or preferred modality for CNS tumors and parameningeal sites.

Indian Academy of Pediatrics (IAP) Pediatric Hemato-Oncology 2025–2026 modules firmly endorse PBT referral for eligible solid tumors, prioritizing CNS, base-of-skull, and re-irradiation cases.
National Cancer Grid protocols emphasize PBT to minimize devastating late effects in survivorship.

Operational centers currently include the Apollo Proton Cancer Centre in Chennai and Tata Memorial’s National Hadron Beam Therapy Facility in Mumbai.
Capacity is expanding with new facilities developing in Delhi, Hyderabad, and Bengaluru under public-private models.

Capital and operational costs remain prohibitively high, frequently costing 15 to 30 lakh rupees per treatment course.
Anesthesia logistics for daily treatment fractions in toddlers pose significant operational challenges.
Limited tertiary centers create profound geographical equity and rural access barriers.

Treatments in empaneled centers are increasingly covered by Ayushman Bharat PM-JAY, the Central Government Health Scheme (CGHS), and the National Policy for Rare Diseases (NPRD).

Modern pencil-beam scanning (PBS) technology actively minimizes historical neutron scatter concerns.
Preclinical 2026 trials of FLASH and ARC proton techniques promise ultra-high dose rates capable of further toxicity reduction.